WuXi Healthcare Ventures has returned for a $57m series B in immunotherapy developer Medeor Therapeutics, with the round led by RA Capital Management.
US-based biotechnology developer Medeor Therapeutics closed a $57m series B round yesterday with investors including WuXi Healthcare Ventures, the corporate venturing arm of medical research firm WuXi PharmaTech.
The oversubscribed round was led by RA Capital Management and also featured Sofinnova Ventures, 6 Dimensions Capital and Vivo Capital.
Founded in 2012, Medeor Therapeutics is working on personalised cellular immunotherapies. Its first candidates focus on kidney transplant patients, where it hopes the treatments will reduce the need for long-term immunosuppression.
The…
